Fidia Farmaceutici, SpA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fidia Farmaceutici, SpA
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.
Pear Therapeutics is developing the Pear-010 digital therapeutic for virtual reality-delivered pain reduction in adults with acute postoperative and postprocedural pain. Its inclusion in FDA’s Safer Technologies Program (STeP) program suggests the FDA is committed to continuing that program for products that treat non-life-threatening or reversible conditions.
The German group is putting another €1.3bn into its Leaps by Bayer investment arm until the end of 2024 to support new companies that are "shifting core paradigms in the sectors of health and agriculture."
Minute Insight: Pear Therapeutics Inks Agreement With SoftBank To Develop Japan-Focused Digital Therapeutic
Pear Therapeutics signed an agreement with SoftBank to develop a Japan-focused digital therapeutic, but regulatory questions remain.
- Other Names / Subsidiaries
- Fidia Pharma Group
- OftaH.T. e Neoox
- Soluciones Bioregenerativas SL
- Sooft Italia
- Fidia Pharma Austria GmbH